Protein-Associated Extracellular Vesicles via Scalable TFF Manufacturing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing clinical-grade extracellular vesicles (EVs) associated with proteins derived from mesenchymal stromal cells (MSCs) face challenges in scalability, reproducibility, and stability, necessitating a need for a reliable and reproducible production process under Good Manufacturing Practice (GMP) conditions, while also requiring specific proteins to enhance therapeutic efficacy.
Innovation Solution
A process involving purification and concentration of EVs via tangential flow filtration (TFF), followed by association with exogenous proteins like Annexin V, Thioredoxin, and Lactadherin, using calcium as a cofactor when necessary, to enhance therapeutic properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional EV purification methods are used, then EVs can be obtained, but scalability is limited and the process becomes labor intensive
Solution Approach 1:
The patent replaces traditional mechanical purification methods (ultracentrifugation, size exclusion chromatography) with tangential flow filtration (TFF), a membrane-based separation system that enables automated, scalable EV purification without manual intervention, directly resolving the contradiction between scalability and labor intensity
Solution Approach 2:
The patent changes the physical parameters of the purification process by using TFF with specific membrane pore sizes (0.1-10 µm) and operating at controlled transmembrane pressures, transforming the purification mechanism from gravity/centrifugal force-dependent to pressure-driven flow through membranes, enabling scalable automated production
2Reliability
If EVs are produced under GMP conditions, then quality consistency is improved, but process complexity increases
Solution Approach 1:
The patent segments the EV production process into distinct modular steps: cell culture, EV isolation via TFF, concentration, protein association, and formulation. Each module can be independently optimized and validated for GMP compliance, managing overall process complexity while ensuring batch uniformity through standardized operating procedures for each segment
Solution Approach 2:
The patent introduces TFF as an intermediary purification step between cell culture and final EV formulation. This intermediate purification stage separates EVs from cell debris and contaminants in a controlled, GMP-compatible manner, ensuring quality consistency without requiring overly complex downstream processing
3Quantity of substance
If EVs are concentrated by traditional methods, then EV concentration increases, but EV stability and shelf life decrease
Solution Approach 1:
The patent replaces traditional concentration methods (ultracentrifugation, freeze-thaw cycles, electroporation) with tangential flow filtration concentration, which concentrates EVs through controlled membrane filtration without subjecting them to mechanical stress, temperature extremes, or electrical fields that compromise EV structural integrity and stability
Solution Approach 2:
The patent changes the concentration approach by using TFF to control transmembrane pressure and flow rates, concentrating EVs gradually under optimized conditions that preserve membrane integrity. This parameter-controlled concentration maintains EV stability while achieving high concentrations suitable for therapeutic applications
4Reliability
If EVs are modified to express therapeutic molecules, then therapeutic efficacy is improved, but manufacturing complexity increases
Solution Approach 1:
The patent applies preliminary action by pre-coating TFF membranes with specific proteins (annexin V, lactadherin, thioredoxin) before EV concentration. This pre-prepared membrane surface enables automatic protein association with EVs during the concentration process itself, incorporating therapeutic molecules without requiring separate modification steps, thus maintaining manufacturing simplicity while enhancing therapeutic efficacy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process ensures the production of stable, reproducible, and clinically effective EVs with enhanced therapeutic potential, meeting GMP standards and maintaining protein association for improved functionality.
Implementation Method 1
a concentration step of the filtrate of said at least one filtration step, wherein said EVs are concentrated by means of tangential flow filtration in a TFF device
Implementation Method 2
association with exogenous proteins like Annexin V, Thioredoxin, and Lactadherin, using calcium as a cofactor when necessary
Data Source
Figure 1
AI summary
The current invention relates to a process for the manufacturing of extracellular vesicles (EVs) associated with proteins, derived from mesenchymal stromal cells (MSCs), said process comprises the steps of: - Purifying EVs from a cell medium comprising MSCs, wherein said purifying occurs via at least one filtration step of said medium; followed by - a concentration step of the filtrate of said at least one filtration step, wherein said EVs are concentrated by means of tangential flow filtration in a TFF device; and - wherein during said TFF step the EVs are associated with one or more exogenous proteins inside of said TFF device, or in a vessel fluidly connected to said TFF device to which said EVs are transferred from said TFF. The current invention also relates to a pharmaceutical composition comprising a therapeutically effective amount of EVs associated with proteins, and the use thereof.